AT1 RECEPTOR AUTOANTIBODIES MEDIATE EFFECTS OF METABOLIC SYNDROME ON DOPAMINERGIC VULNERABILITY.
Prif Awduron: | Ana Isabel Rodríguez Pérez, María A Pedrosa, Carmen M Labandeira, Rita Valenzuela, Aloia Quijano, Mariña Sanchez-Andrade, Juan Antonio Suárez-Quintanilla, Jose Lanciego, José Luis Labandeira-García |
---|---|
Fformat: | Erthygl |
Iaith: | English |
Cyhoeddwyd: |
Elsevier
2023-10-01
|
Cyfres: | IBRO Neuroscience Reports |
Mynediad Ar-lein: | http://www.sciencedirect.com/science/article/pii/S2667242123010126 |
Eitemau Tebyg
-
ANGIOTENSIN TYPE-1 RECEPTOR AND ACE2 AUTOANTIBODIES IN PARKINSON´S DISEASE
gan: Ana Isabel Rodríguez Pérez, et al.
Cyhoeddwyd: (2023-10-01) -
Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease
gan: Carmen M. Labandeira, et al.
Cyhoeddwyd: (2022-06-01) -
Angiotensin type-1 receptor autoantibodies promote alpha-synuclein aggregation in dopaminergic neurons
gan: Lucia Lage, et al.
Cyhoeddwyd: (2024-11-01) -
Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment
gan: Jose L. Labandeira-Garcia, et al.
Cyhoeddwyd: (2022-02-01) -
Brain renin-angiotensin system and dopaminergic cell vulnerability
gan: Jose L Labandeira-Garcia, et al.
Cyhoeddwyd: (2014-07-01)